Patent intelligence · US
US 8409616
Extended release opioid abuse deterrent compositions and methods of making same
Extended release opioid abuse deterrent compositions and methods of making same
Patent details — US 8409616
- Jurisdiction
- US
- Status
- granted
- Grant date
- Apr 2, 2013
- Expiration
- Mar 28, 2033
- Applicant
- Acurx Pharmaceuticals, Inc.
- Claims
- 17
- CPC classes
- A61K, A61K31/485, A61K47/32, A61K47/34
Quick answer
US 8409616 (Extended release opioid abuse deterrent compositions and methods of making same) is held by Acurx Pharmaceuticals, Inc.. Status: granted. Granted Apr 2, 2013. Expires Mar 28, 2033 (7 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Acurx Pharmaceuticals, Inc.
- Grant date
- Expiration
- Claims
- 17
- CPC classes
- A61K, A61K31/485, A61K47/32, A61K47/34, A61K47/38, A61K9/2009
More from Acurx Pharmaceuticals, Inc.
Related pharmaceutical patents in our USPTO index.
-
US 12036225
Use of ibezapolstat to promote microbiome health
granted -
US 11857629
Methods and compositions for self-regulated release of active pharmaceutical ingredient
granted -
US 11723885
Methods and compositions for interfering with extraction or conversion of a drug susceptible to abuse
granted -
US 11554114
Methods and compositions for self-regulated release of active pharmaceutical ingredients
granted -
US 11197837
Methods and compositions for interfering with extraction or conversion of a drug susceptible to abuse
granted -
US 11103581
Methods and compositions for self-regulated release of active pharmaceutical ingredient
granted -
US 11083794
Methods and compositions for self-regulated release of active pharmaceutical ingredient
granted -
US 11001592
DNA polymerase IIIC inhibitors and use thereof
granted
Frequently asked questions
What is US patent 8409616?
US 8409616 (Extended release opioid abuse deterrent compositions and methods of making same) is held by Acurx Pharmaceuticals, Inc.. Status: granted. Granted Apr 2, 2013. Expires Mar 28, 2033 (7 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 8409616?
Acurx Pharmaceuticals, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 28 pharmaceutical patents for this assignee.
When does US 8409616 expire?
Our index shows an expiration date of Mar 28, 2033 (7 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.